Latest Angiogenesis Stories
Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.
Researchers are gaining insight on how to slow the growth of tumors via angiogenesis inhibitors.
Researchers have gained a new understanding of the way in which growing tumors are fed and how this growth can be slowed via angiogenesis inhibitors that eliminate the blood supply to tumors.
FORT WORTH, Texas, Aug. 4, 2011 /PRNewswire/ -- Healthpoint Biotherapeutics today announced positive topline results for its Phase IIb clinical trial investigating the efficacy of HP802-247 in venous leg ulcers.
Melanoma is devastating on many fronts: rates are rising dramatically among young people, it is deadly if not caught early, and from a biological standpoint, the disease tends to adapt to even the most modern therapies, known as VEGF inhibitors.
Scientists at the University of Southampton have developed smart nanomaterials, which can disrupt the blood supply to cancerous tumors.
Massachusetts General Hospital (MGH) researchers have discovered the first of an entirely new class of antiangiogenesis drugs â€“ agents that interfere with the development of blood vessels.
BARCELONA, Spain, June 23, 2011 /PRNewswire/ -- CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented pre-clinical research results at the European Society for Medical Oncology (ESMO) 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor...
SAN DIEGO, June 22, 2011 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced the selection of the Cedars-Sinai Medical Center Nuclear Cardiology Core Laboratory (Cedars-Sinai Core Laboratory), Los Angeles, California, to serve as the central core lab for the Company's Generx ASPIRE clinical study.
TARRYTOWN, N.Y., June 17, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced that NASDAQ has halted trading of the company's common stock today. The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S.
- To swell, as grain or wood with water.